- |||||||||| hydroxychloroquine / Generic mfg.
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy (clinicaltrials.gov) - Feb 5, 2018 P2, N=60, Completed, Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Apr 2017 Recruiting --> Completed | Trial primary completion date: Aug 2018 --> Jan 2018 | Trial completion date: Aug 2018 --> Jan 2018 | Initiation date: Aug 2016 --> Sep 2016
- |||||||||| bortezomib / Generic mfg.
Trial completion, Enrollment change: Pilot Study of Velcade® in IgA Nephropathy (clinicaltrials.gov) - Aug 10, 2017 P4, N=11, Completed, Active, not recruiting --> Completed Recruiting --> Completed | N=15 --> 11
- |||||||||| losartan potassium / Generic mfg.
Enrollment closed, Trial primary completion date: Efficacy and Safety of Losartan in Children With Ig A Nephropathy (clinicaltrials.gov) - Jul 17, 2017 P3, N=37, Active, not recruiting, Recruiting --> Completed | N=15 --> 11 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Enrollment change, Trial withdrawal: Acthar on Proteinuria in IgA Nephropathy Patients (clinicaltrials.gov) - Apr 5, 2017 P4, N=0, Withdrawn, Trial primary completion date: Dec 2018 --> Mar 2017 N=26 --> 0 | Recruiting --> Withdrawn
- |||||||||| bortezomib / Generic mfg.
Enrollment change, Trial primary completion date: Pilot Study of Velcade® in IgA Nephropathy (clinicaltrials.gov) - Jan 22, 2016 P4, N=15, Recruiting, Recruiting --> Active, not recruiting | N=20 --> 5 N=10 --> 15 | Trial primary completion date: Jul 2016 --> Jul 2017
- |||||||||| Tavalisse (fostamatinib) / Rigel
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy (clinicaltrials.gov) - Oct 23, 2015 P2, N=0, Withdrawn, Active, not recruiting --> Completed N=25 --> 0 | Initiation date: Jun 2015 --> Sep 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2017 --> Sep 2015
- |||||||||| bortezomib / Generic mfg.
Trial primary completion date: Pilot Study of Velcade® in IgA Nephropathy (clinicaltrials.gov) - Jan 30, 2015 P4, N=10, Recruiting, Withdrawn --> Terminated; low-rate of enrollment Trial primary completion date: Jul 2015 --> Jul 2016
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date: Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy (clinicaltrials.gov) - Nov 20, 2014 P4, N=54, Active, not recruiting, Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Sep 2015
- |||||||||| mycophenolate mofetil / Generic mfg.
Trial termination: Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (clinicaltrials.gov) - Oct 2, 2014 P3, N=184, Terminated, Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Sep 2015 Completed --> Terminated; DSMB recommended stopping the trial because of lack of effect.
- |||||||||| bortezomib / Generic mfg.
Trial primary completion date: Pilot Study of Velcade® in IgA Nephropathy (clinicaltrials.gov) - Jun 12, 2014 P4, N=10, Recruiting, Trial primary completion date: Jun 2014 --> Dec 2015 Trial primary completion date: Jul 2014 --> Jul 2015
|